Post-EHA 2026 Lymphoma Highlights

Featuring presentations & discussions on selected Lymphoma abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Krish Patel | Moderators: Joanna Rhodes & Toby Eyre

The Post-EHA 2026 Lymphoma Highlights has been supported by AstraZeneca (Diamond Sponsor) and Genentech (Gold Sponsor). Supporters have no influence over the production of content.

Preliminary Agenda (subject to change)

Session 1: Advances in frontline therapy and risk-adapted management for LBCL & DLBCL

High-dose methotrexate does not reduce risk of CNS relapse in ultra high-risk large B-cell lymphoma: An international retrospective analysis of 1,923 patients (Abstract S249) | Speaker: Matthew Wilson 

Epcoritamab + R-MINI-CHOP results in 2-year remissions and high MRD-negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial (Abstract PF1007) | Speaker: Chan Cheah

Tafasitamab plus lenalidomide and R-CHOP for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the Phase 3 FRONTMIND study (Abstract S101) | Speaker: Umberto Vitolo

Panel discussion 

Session 2: Novel antibody-based approaches in R/R LBCL

Mosunetuzumab plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: Updated efficacy and safety from the Phase 3 SUNMO study including in patient subgroups (Abstract PF968) | Speaker: Jason Westin

Results from EPCORE DLBCL-1: Randomized Phase 3 study of epcoritamab (EPCOR) vs investigator’s choice chemoimmunotherapy (CIT) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) (Abstract S235) | Speaker: Christopher Fox

Five-year follow-up of patients with relapsed/refractory large B-cell lymphoma who achieved a complete response with glofitamab monotherapy (Abstract PF963) | Speaker: Krish Patel

Panel discussion 

Session 3: Recent progress in FL 

Safety and efficacy of subcutaneous mosunetuzumab plus lenalidomide induction therapy followed by mosunetuzumab maintenance in previously untreated follicular lymphoma (Abstract S226) | Speaker: Emmanuel Bachy

Phase 3 INMIND study of tafasitamab (TAFA) plus lenalidomide (LEN) and rituximab (R) for relapsed or refractory follicular lymphoma (R/R FL): Outcomes in patients with or without high-risk factors (Abstract PS2048) | Speaker: Paolo Strati

Surovatamig (AZD0486) plus rituximab in previously untreated follicular lymphoma (FL): INITIAL SAFETY Data from the Phase 3 SOUNDTRACK-F1 trial (Abstract S228) | Speaker: Chan Cheah

Rituximab (R), golcadomide (GOLCA) +/- nivolumab (N) in treatment-naive follicular lymphoma (FL). Primary results of the investigator-led randomised Phase II TOP-FLOR study (Abstract PF937) | Speaker: Eliza Hawkes

Anchored matching-adjusted indirect comparison of epcoritamab, lenalidomide, and rituximab vs tafasitamab, lenalidomide, and rituximab in relapsed/refractory follicular lymphoma: EPCORE FL-1 vs INMIND (Abstract PS2035) | Speaker: Kim Linton

Panel discussion 

Conclusions and webinar close